Online inquiry

IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15710MR)

This product GTTS-WQ15710MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15710MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3279MR IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ7265MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ3850MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-054
GTTS-WQ2502MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ9921MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ6503MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ15090MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ12951MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW